TY - JOUR
T1 - Effects of probiotic supplementation on anthropometric and metabolic characteristics in adults with metabolic syndrome
T2 - A systematic review and meta-analysis of randomized clinical trials
AU - Hadi, Amir
AU - Arab, Arman
AU - Khalesi, Saman
AU - Rafie, Nahid
AU - Kafeshani, Marzieh
AU - Kazemi, Maryam
N1 - Publisher Copyright:
© 2021 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism
PY - 2021/7
Y1 - 2021/7
N2 - Aims: We conducted a systematic review and meta-analysis to evaluate evidence from randomized controlled trials (RCTs) documenting the effectiveness of supplementation with pro-/synbiotics versus placebo controls on anthropometric and metabolic (glucoregulatory status, lipid profile) indices in adults with metabolic syndrome (MetS). Methods: Databases of MEDLINE, Scopus, Embase, Web of Science, and Cochrane Library were searched through March 2020 to identify eligible RCTs evaluating the effects of pro-/synbiotic consumption in adults (≥18 years) with MetS. Mean differences (MDs) and 95% confidence intervals (CIs) were pooled using random-effects models. Results: Ten eligible publications (9 RCTs, n = 344 participants) were included. Supplementation with pro-/synbiotics reduced total cholesterol (TC) in adults with MetS versus placebo (MD: −6.66 mg/dL, 95% CI: −13.25 to −0.07, P = 0.04, I2 = 28.8%, n = 7), without affecting weight, body mass index, waist circumference, fasting blood sugar, homeostasis model assessment for insulin resistance, insulin, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol (P > 0.05). Conclusions: Pro-/synbiotic consumption may be beneficial in reducing TC levels in adults with MetS. However, our observations do not support the effectiveness of pro-/synbiotics consumption on other anthropometric or metabolic outcomes of MetS. Further investigations with larger sample sizes are required to confirm these findings.
AB - Aims: We conducted a systematic review and meta-analysis to evaluate evidence from randomized controlled trials (RCTs) documenting the effectiveness of supplementation with pro-/synbiotics versus placebo controls on anthropometric and metabolic (glucoregulatory status, lipid profile) indices in adults with metabolic syndrome (MetS). Methods: Databases of MEDLINE, Scopus, Embase, Web of Science, and Cochrane Library were searched through March 2020 to identify eligible RCTs evaluating the effects of pro-/synbiotic consumption in adults (≥18 years) with MetS. Mean differences (MDs) and 95% confidence intervals (CIs) were pooled using random-effects models. Results: Ten eligible publications (9 RCTs, n = 344 participants) were included. Supplementation with pro-/synbiotics reduced total cholesterol (TC) in adults with MetS versus placebo (MD: −6.66 mg/dL, 95% CI: −13.25 to −0.07, P = 0.04, I2 = 28.8%, n = 7), without affecting weight, body mass index, waist circumference, fasting blood sugar, homeostasis model assessment for insulin resistance, insulin, triglyceride, low-density lipoprotein cholesterol, or high-density lipoprotein cholesterol (P > 0.05). Conclusions: Pro-/synbiotic consumption may be beneficial in reducing TC levels in adults with MetS. However, our observations do not support the effectiveness of pro-/synbiotics consumption on other anthropometric or metabolic outcomes of MetS. Further investigations with larger sample sizes are required to confirm these findings.
KW - Clinical trials
KW - Meta-Analysis
KW - Metabolic syndrome
KW - Probiotics
KW - Synbiotics
UR - https://www.scopus.com/pages/publications/85109079477
U2 - 10.1016/j.clnu.2021.05.027
DO - 10.1016/j.clnu.2021.05.027
M3 - Article
C2 - 34237694
AN - SCOPUS:85109079477
SN - 0261-5614
VL - 40
SP - 4662
EP - 4673
JO - Clinical Nutrition
JF - Clinical Nutrition
IS - 7
ER -